Wedbush raised the firm’s price target on Stoke Therapeutics (STOK) to $36 from $32 and keeps an Outperform rating on the shares. The firm notes Stoke pulled forward Phase 3 EMPEROR zorevunersen enrollment completion timing to Q2 2026, which shifts data to mid-2027. The company continues to observe strong patient interest, and Wedbush wonders if enrollment completion could move even earlier.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STOK:
- Stoke Therapeutics Accelerates Phase 3 Dravet Study Timeline
- Stoke Therapeutics updates timeline for Phase 3 EMPEROR study
- Stoke Therapeutics price target raised to $36 from $28 at Canaccord
- Stoke Therapeutics price target raised to $50 from $35 at H.C. Wainwright
- Stoke Therapeutics Highlights Zorevunersen’s Potential at Epilepsy Meeting